CCM
GILD icon

Consolidated Capital Management’s Gilead Sciences GILD Stock Holding History

Consolidated Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,010
Closed -$359K – 40
2016
Q4 		$359K Buy
+5,010
New +$372K 0.71% 27

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Consolidated Capital Management's GILD Position: Q1 2017 in Review

Consolidated Capital Management sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 5,010 shares — an estimated $359K sold.

Consolidated Capital Management first reported a position in GILD in Q4 2016 and held it in 1 quarter. The position peaked at $359K in Q4 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Consolidated Capital Management reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Consolidated Capital Management sold 5,010 Gilead Sciences shares in Q1 2017, an estimated $359K.
  • Consolidated Capital Management first reported a position in Gilead Sciences in Q4 2016 and held it in 1 quarter.
  • Consolidated Capital Management's Gilead Sciences position peaked at $359K in Q4 2016.
  • 1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Consolidated Capital Management's 13F filing for Q1 2017, filed 12 May 2017.